International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Luciano J Costa¹, Rahul Banerjee², Hira Mian³, Katja Weisel⁴, Susan Bal⁵, Benjamin A Derman⁶, Maung M Htut⁷, Chandramouli Nagarajan⁸, Cesar Rodriguez⁹, Joshua Richter⁹, Matthew J Frigault¹⁰, Jing C Ye¹¹, Niels W C J van de Donk¹², Peter M Voorhees¹³, Benjamin Puliafito¹⁰, Nizar Bahlis¹⁴, Rakesh Popat¹⁵, Wee Joo Chng¹⁶, P Joy Ho¹⁷, Gurbakhash Kaur⁹, Prashant Kapoor¹⁸, Juan Du¹⁹, Fredrik Schjesvold²⁰, Jesus Berdeja²¹, Hermann Einsele²², Adam D Cohen²³, Joseph Mikhael^{24

25}, Yelak Biru²⁵, S Vincent Rajkumar¹⁸, Yi Lin¹⁸, Thomas G Martin²⁶, Ajai Chari²⁶

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ljcosta@uabmc.edu.
² Division of Hematology and Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Department of Oncology, McMaster University, Hamilton, ON, Canada.
⁴ University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁵ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
⁶ Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
⁷ Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, CA, USA.
⁸ Singapore General Hospital, Singapore, Singapore.
⁹ Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA.
¹⁰ Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
¹¹ MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
¹² Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
¹³ Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC, USA.
¹⁴ Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
¹⁵ NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁶ National University Cancer Institute, Singapore, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
¹⁷ Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia.
¹⁸ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
¹⁹ Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
²⁰ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
²¹ Greco-Hainsworth Centers for Cancer Research, Tennessee Oncology, Nashville, TN, USA.
²² Department of Internal Medicine II, University Hospital, Wurzburg, Germany.
²³ University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA.
²⁴ Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
²⁵ International Myeloma Foundation, Studio City, CA, USA.
²⁶ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

PMID: 39870767
PMCID: PMC11879857
DOI: 10.1038/s41375-024-02482-6

Review

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Luciano J Costa et al. Leukemia. 2025 Mar.

. 2025 Mar;39(3):543-554.

doi: 10.1038/s41375-024-02482-6. Epub 2025 Jan 27.

Authors

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. ljcosta@uabmc.edu.
² Division of Hematology and Oncology, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Department of Oncology, McMaster University, Hamilton, ON, Canada.
⁴ University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁵ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
⁶ Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
⁷ Division of Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, CA, USA.
⁸ Singapore General Hospital, Singapore, Singapore.
⁹ Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA.
¹⁰ Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
¹¹ MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
¹² Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
¹³ Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC, USA.
¹⁴ Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
¹⁵ NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁶ National University Cancer Institute, Singapore, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
¹⁷ Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia.
¹⁸ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
¹⁹ Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
²⁰ Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
²¹ Greco-Hainsworth Centers for Cancer Research, Tennessee Oncology, Nashville, TN, USA.
²² Department of Internal Medicine II, University Hospital, Wurzburg, Germany.
²³ University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA.
²⁴ Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
²⁵ International Myeloma Foundation, Studio City, CA, USA.
²⁶ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

PMID: 39870767
PMCID: PMC11879857
DOI: 10.1038/s41375-024-02482-6

Abstract

T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.

PubMed Disclaimer

Conflict of interest statement

Competing interests: LJC: Honoraria (Amgen, Bristol-Myers-Squibb, AbbVie, Pfizer, Johnson & Johnson, Adaptive Biotechnologies, Sanofi, Genentech/Roche), Research Funding (Amgen, Bristol-Myers-Squibb, Johnson & Johnson, AbbVie, Caribou, Gracell, Genentech/Roche); RB: Honoraria (Bristol-Myers-Squibb, Pfizer, Adaptive Biotechnologies, Caribou, Genentech/Roche, GSK, Karyopharm, Legend Biotech, Johnson & Johnson, SparkCures), Research Funding (AbbVie, Bristol-Myers-Squibb, Johnson & Johnson, Novartis, Pack Health, Prothena, Sanofi); HM: Honoraria (Bristol-Myers-Squibb, Pfizer, GSK, Karyopharm, AbbVie) Research Funding (Pfizer); SB: Honoraria (AbbVie, Adaptive Biotechnologies, Bristol-Myers-Squibb, Johnson & Johnson, MJH Lifesciences); BD: Honoraria (Sanofi, Johnson & Johnson, Canopy, COTA, Bristol-Myers-Squibb) Research Funding (Amgen, GSK); CN: Honoraria (Johnson & Johnson); JR: Honoraria (Janssen, Bristol-Myers-Squibb, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, AbbVie, Regeneron, Forus, Menarini, Adaptive Biotechnologies); KW:Honoraria (Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda) Research Funding (Amgen, BMS/Celgene, Janssen, Sanofi; GSK, Abbvie) Consultancy (Abbvie, Amgen, Adaptive Biotech, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Takeda); MJF: Honoraria (Kite/Gilead, CMS, Novartis, Janssen, Legend, Cytoagents, SITC); JCY: Honoraria (Janssen, Sanofi, Bristol-Myers-Squibb, Regeneron, GSK, Pfizer, Menarini); NWCJvdD: Honoraria (Janssen, Amgen, Celgene, Novartis, Cellectis, Bristol-Myers-Squibb/Celgene, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Pfizer, AbbVie, Servier) Research Funding (Janssen, Amgen, Bristol-Myers-Squibb/Celgene, Novartis, Cellectis); NB: Honoraria (AbbVie, Amgen, Bristol-Myers-Squibb, Forus, Genentech, GlaxoSmithKline, Janssen, Pfizer, Sanofi, Takeda) Research Funding (Pfizer); RP: Honoraria (GSK, Pfizer, Janssen, Bristol-Myers-Squibb, Abbvie, Roche) Research Funding (GSK, Pfizer); W-JC: Honoraria (AbbVie, Amgen, Pfizer, Sanofi, Regeneron, GSK, Novartis) Research Funding (Bristol-Myers-Squibb, Janssen, Novartis); PJH: Advisory Board without honoraria (Antengene, Gilead, iTeos Therapeutics, GSK, Janssen, Pfizer), Research Funding: Novartis; GK: Honoraria (Janssen, Bristol-Myers-Squibb, Sanofi, Kite, Arcellx, Pfizer, Kedrion, Cellectar); PK: Research Funding (Takeda Pharmaceuticals, Celgene, Sanofi, AbbVie, Karyopharm Therapeutics, Sorrento Therapeutics, Ichnos Sciences, Amgen); FS: Honoraria (AbbVie, GSK, Celgene, Takeda, Janssen, Oncopeptides, Sanofi, Bristol-Myers-Squibb, Novartis, SkyliteDX, Pfizer, Daiki-Sankyo,); JB: Honoraria (AstraZeneca, Bristol-Myers-Squibb, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, Takeda) Research Funding (2 Seventy Bio, Abbvie, Amgen, Bristol-Myers-Squibb, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Takeda); HE: Honoraria (Bristol-Myers-Squibb, Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, Roche), Research Funding (BMS/Celgene, Janssen, Sanofi; GSK, Amgen) Consultancy (Amgen, BMS, Celgene, Janssen, GSK, Novartis, Roche, Sanofi, Takeda); ADC: Honoraria (GSK; Bristol-Myers-Squibb, Janssen, AbbVie, Pfizer, iTeos, Ichnos, Arcellx, Legend; Genentech/Roche, Novartis, AstraZeneca, Kite); Research Funding (GSK, Genentech, Janssen, BMS); Patent (Novartis); JM: Honoraria (Amgen, Sanofi, Bristol-Myers-Squibb, Janssen, Takeda); YL: Honoraria (Janssen, Sanofi, NexImmune, Caribou, Bristol-Myers-Squibb, Pfizer, Regeneron, Genentech; Sanofi, Regeneron) Research Funding (Janssen, Bristol-Myers-Squibb); TGM: Honoraria (GSK, Sanofi, Amgen, Janssen); AC: Honoraria (AbbVie, Adaptive biotechnologies, Amgen, Angengene, Bristol-Myers-Squibb, Forus, Genentech/Roche, GSK, Janssen, Karyopharm, Millenium/Takeda, Sanofi). The remaining authors declare no conflict of interest. The work presented in this manuscript did not receive any financial or material support.

Figures

**Fig. 1**
Distinction between holding therapy (HT), bridging therapy (BT), and lymphodepletion chemotherapy (LDC) in the care of the patient with multiple myeloma undergoing CAR T-cell therapy.

See this image and copyright information in PMC

References

1. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002–14. - PubMed
1. San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389:335–47. - PubMed
1. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. - PubMed
1. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. - PubMed
1. Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387:495–505. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Affiliations

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials